---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-016046"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:34:08.772251+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026

## Summary
- Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.
- Preclinical DME model: oral BGE-102 achieved near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity.
- BGE-102 ongoing Phase 1 shows favorable tolerability and robust reductions in hsCRP, IL-6, and IL-1β.
- Additional milestones: 1H2026 complete Phase 1, start CV risk Phase 2a; 2H2026 CV risk data.
- Cites growing clinical evidence for targeting inflammation in retinal diseases, including intravitreal IL-6 inhibitors.

## SEC filing metadata
- accession: 0001193125-26-016046
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526016046/0001193125-26-016046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526016046/bioa-20260120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-016046
- JSON: https://secwatch.observer/filing/0001193125-26-016046.json
- Plain text: https://secwatch.observer/filing/0001193125-26-016046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.